This means that at least 78% (7/9 patients) MSI-High lesions detected with the LMR panel were LS (based on germline MMR mutations) or probable LS (based MSI-High tumor phenotype, loss of MMR expression by IHC, lack of BRAF V600E mutation, early age of onset and cancer history). This evidence concerns the gene BRAF and neoplasm.